Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

PHI-501

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Pharos iBT

Drug class:

NRAS inhibitor

Related drugs:

‹

Undisclosed NRAS inhibitor (0)

exoASO-NRAS (0)

Undisclosed NRAS inhibitor (0)

exoASO-NRAS (0)

›

NRAS mutation	Acute Myelogenous Leukemia	NRAS mutation	Acute Myelogenous Leukemia	PHI-501 Sensitive: D – Preclinical PHI-501 Sensitive : D	PHI-501 Sensitive: D – Preclinical PHI-501 Sensitive : D
NRAS Q61R	Melanoma	NRAS Q61R	Melanoma	PHI-501 Sensitive: D – Preclinical PHI-501 Sensitive : D	PHI-501 Sensitive: D – Preclinical PHI-501 Sensitive : D
BRAF G464E	Melanoma	BRAF G464E	Melanoma	PHI-501 Sensitive: D – Preclinical PHI-501 Sensitive : D	PHI-501 Sensitive: D – Preclinical PHI-501 Sensitive : D
BRAF V600E	Melanoma	BRAF V600E	Melanoma	PHI-501 Sensitive: D – Preclinical PHI-501 Sensitive : D	PHI-501 Sensitive: D – Preclinical PHI-501 Sensitive : D
NRAS mutation	Melanoma	NRAS mutation	Melanoma	PHI-501 Sensitive: D – Preclinical PHI-501 Sensitive : D	PHI-501 Sensitive: D – Preclinical PHI-501 Sensitive : D